Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:EVLONASDAQ:HROWNASDAQ:RVLP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.20+4.8%$1.65$1.43▼$4.83$220.90M1.57153,929 shs140,582 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.06$9K0.7414,287 shs225 shsHROWHarrow$31.17+3.4%$25.68$16.87▼$59.23$1.14B0.4499,200 shs532,210 shsRVLPRVL Pharmaceuticals$0.04$0.03▼$1.91N/AN/AN/A63.96 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune+4.76%+33.33%+31.74%-5.17%-51.22%EVLOEvelo Biosciences0.00%-75.00%+66.67%0.00%-16.67%HROWHarrow+3.38%+6.24%+27.75%+38.16%+75.70%RVLPRVL Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.3095 of 5 stars3.52.00.00.03.30.80.6EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AHROWHarrow2.3695 of 5 stars3.51.00.00.02.72.50.6RVLPRVL PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00445.45% UpsideEVLOEvelo Biosciences 0.00N/AN/AN/AHROWHarrow 3.00Buy$61.2596.50% UpsideRVLPRVL Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HROW, RVLP, ACIU, and EVLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/12/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $60.005/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025HROWHarrowB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$69.00 ➝ $65.003/31/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.003/18/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.003/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M7.81N/AN/A$2.12 per share1.04EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AHROWHarrow$212.86M5.37N/AN/A$2.01 per share15.51RVLPRVL Pharmaceuticals$49.72M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)EVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A7/7/2025 (Estimated)HROWHarrow-$24.41M-$0.56N/A77.93N/A-19.75%-45.57%-8.87%8/6/2025 (Estimated)RVLPRVL Pharmaceuticals-$51.69MN/A0.00N/AN/AN/AN/AN/AN/ALatest HROW, RVLP, ACIU, and EVLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million3/27/2025Q4 2024HROWHarrow$0.11$0.25+$0.14$0.24$66.01 million$66.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ARVLPRVL PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86EVLOEvelo BiosciencesN/AN/AN/AHROWHarrow3.231.551.44RVLPRVL PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%EVLOEvelo Biosciences0.31%HROWHarrow72.76%RVLPRVL Pharmaceuticals14.36%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%EVLOEvelo Biosciences1.02%HROWHarrow15.16%RVLPRVL Pharmaceuticals4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataHROWHarrow18236.69 million30.75 millionOptionableRVLPRVL Pharmaceuticals125111.41 million106.50 millionOptionableHROW, RVLP, ACIU, and EVLO HeadlinesRecent News About These CompaniesUnravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett SyndromeMay 28, 2024 | tmcnet.comRaval ICS Ltd.May 17, 2024 | wsj.comRVLPQ RVL Pharmaceuticals plcMarch 2, 2024 | seekingalpha.comRVL Pharmaceuticals PLC RVLPQJanuary 11, 2024 | morningstar.comRVL Pharmaceuticals plc’s latest rating changes from various analystsOctober 18, 2023 | knoxdaily.comRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For BankruptcyOctober 13, 2023 | marketwatch.comSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | benzinga.comRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be CancelledOctober 12, 2023 | markets.businessinsider.comRVL Pharmaceuticals Subsidiaries File for BankruptcyOctober 12, 2023 | finance.yahoo.comRVL Pharmaceuticals plc [RVLP] Investment Guide: What You Need to KnowOctober 11, 2023 | knoxdaily.comWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?October 6, 2023 | investorplace.comInvesting in RVL Pharmaceuticals plc [RVLP]: What You Must KnowOctober 4, 2023 | knoxdaily.comUnderstanding the Risks of Investing in RVL Pharmaceuticals plc (RVLP)September 27, 2023 | knoxdaily.comRVLP Shares Experience Surge in ValueSeptember 21, 2023 | knoxdaily.comExamining the Potential Price Growth of RVL Pharmaceuticals plc (RVLP)September 13, 2023 | knoxdaily.comAnalysts predict RVLP shares will perform strongly in 2023September 7, 2023 | knoxdaily.comRVL Pharmaceuticals plc [RVLP] Investment Appeal on the RiseAugust 23, 2023 | knoxdaily.comUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | finance.yahoo.comRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. WainwrightAugust 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHROW, RVLP, ACIU, and EVLO Company DescriptionsAC Immune NASDAQ:ACIU$2.20 +0.10 (+4.76%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$2.17 -0.03 (-1.55%) As of 06/10/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 06/9/2025 09:30 AM EasternEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Harrow NASDAQ:HROW$31.17 +1.02 (+3.38%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$31.20 +0.03 (+0.11%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.RVL Pharmaceuticals NASDAQ:RVLPRVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
